{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-031856","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.866606+00:00","generated_at":"2026-05-17T01:56:09.170653+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC","bullets":["REQORSA overexpressed TUSC2 tumor suppressor gene in ALK-EML4+ NSCLC cell lines and patient derived organoids.","Treatment induced apoptosis in ALK+ cells, including those resistant to alectinib; combination with alectinib further increased apoptosis.","In mouse xenograft model, REQORSA + alectinib improved survival vs control, suggesting potential for future clinical trial.","Data presented at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-031856","json":"https://secwatch.observer/filing/0001437749-25-031856.json","markdown":"https://secwatch.observer/filing/0001437749-25-031856.md","text":"https://secwatch.observer/filing/0001437749-25-031856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925031856/0001437749-25-031856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925031856/gnpx20251024c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:56:09.170653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}